Adopted Trials - Bowel(rectal)
Acronym: EXCITE
Full Title
A phase I/II trial from the North West/North Wales Clinical Oncology Group on behalf of the NCRI rectal cancer subgroup examining the toxicity and efficacy of Cetuximab, Capecitabine and Irinotecan in combination with radiotherapy as preoperative downstaging treatment for MRI-defined locally advanced rectal cancer
Treatment: Chemotherapy
Phase: 1/2
Current status: Open to recruitment
Chief Investigator: Dr Simon Gollins
Type of trial: Early Phase
Website:
